Form 4: Humana CEO Rechtin Reports Stock Activity

Humana Inc. President & CEO James A. Rechtin reported routine stock acquisitions and dispositions related to equity awards and tax obligations.

Summary

• James A. Rechtin, President & CEO of Humana Inc., reported changes in his beneficial ownership of Humana Common Stock.
• On December 15, 2025, Mr. Rechtin acquired 7,707 shares of Humana Common Stock at a price of $0, likely related to the vesting or exercise of equity awards.
• On the same date, he disposed of 3,372 shares of Humana Common Stock at a price of $270.155. This disposition was for the payment of tax liability for shares vesting on December 15, 2025, with no value received in return.
• Following these transactions, Mr. Rechtin indirectly beneficially owns 27,102 shares, which includes 14,054 restricted stock units.
• He also holds 29,230 stock options with an exercise price of $458.185 and an expiration date of January 8, 2031.
• Additionally, he holds 15,772 stock options with an exercise price of $367.21 and an expiration date of February 21, 2031.
• Mr. Rechtin holds 4,366 restricted stock units, which represent a contingent right to receive one share of Humana Inc. common stock per unit.

Sentiment

Score: 6

Explanation: The filing details routine executive stock transactions, including the vesting of equity awards and subsequent tax-related dispositions. The net effect on beneficial ownership is a slight increase from the vesting, offset by tax sales, which is a standard practice and generally viewed as neutral to slightly positive due to the underlying vesting.

Positives

• The acquisition of 7,707 shares, even at a $0 price, indicates the vesting and realization of equity compensation, aligning executive interests with shareholder value.
• The continued holding of a significant number of shares (27,102 indirectly owned) and derivative securities (options and RSUs) demonstrates ongoing commitment to the company's performance.

Negatives

• The disposition of 3,372 shares, while for tax purposes, reduces the direct beneficial ownership of common stock.

Future Outlook

The vesting schedules for stock options and restricted stock units extend through January and February 2027, indicating future equity compensation realization for the President & CEO. The options have expiration dates in 2031, providing a long-term incentive horizon.

Industry Context

This filing details routine executive compensation transactions for Humana Inc.'s President & CEO. Such transactions are common across the healthcare and insurance industry, reflecting standard practices for aligning executive incentives with long-term company performance through equity awards.

Stakeholder Impact

• Shareholders: The transactions are routine and reflect standard executive compensation practices, aligning management's long-term interests with shareholder value through equity ownership. The tax-related sale is a common occurrence and not indicative of a lack of confidence.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Future vesting of 29,230 stock options in annual increments on January 8, 2026, and January 8, 2027.
• Future vesting of 15,772 stock options in annual increments on February 21, 2026, and February 21, 2027.
• Future vesting of 4,366 restricted stock units in annual increments on January 8, 2026, and January 8, 2027.

Key Dates

Keywords

Humana, HUM, James A. Rechtin, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Executive Compensation, Beneficial Ownership